Effects of statin therapy on atherosclerosis progression, inflammation and lipid profiles in patients with systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials
In brief
Statins cut LDL cholesterol by roughly 35 mg/dL in lupus patients
In six randomized trials involving 668 systemic lupus erythematosus patients, statin therapy lowered LDL by about 35 mg/dL and reduced total cholesterol and hs-CRP levels, but it did not change carotid wall thickness, coronary calcium scores, or disease activity scores. The evidence is low certainty, so larger long-term trials are needed to confirm any cardiovascular benefit.
- Journal
- Autoimmunity reviews (Q1)
- Published
- 29 July 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Natanael de Paula Portilho, Eline Rozária Ferreira Barbosa, Muhammad Younas, William Jakymiu Furtado, Kauê Abreu Chagas, Fabrício Perlucci Machado, et al.
- PMID
- 42526780
- DOI
- 10.1016/j.autrev.2026.104153
Why clinicians should know about it
- Picked for Rheumatology (top studies of the week, 2 August 2026): Statin therapy reduces inflammatory markers in SLE patients
Abstract
BACKGROUND: Patients with systemic lupus erythematosus (SLE) present a markedly increased risk of premature atherosclerosis. Statins have been proposed as a possible therapeutic option to reduce cardiovascular risk in this population; however, their efficacy remains uncertain. This systematic review and meta-analysis assessed the impact of statin therapy on atherosclerosis markers and lipid profiles in SLE patients. MATERIAL AND METHODS: We searched PubMed, EMBASE, and Cochrane for randomized controlled trials (RCTs) comparing statins versus placebo in patients with SLE. Eligible studies reported outcomes including carotid intima-media thickness (CIMT), coronary artery calcium score (CAC), high-sensitivity C-reactive protein (hs-CRP), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), LDL cholesterol, and total cholesterol. Mean differences (MD) and standardized mean differences (SMD) with 95% confidence intervals (CI) were pooled using random-effects models. RESULTS: Six RCTs (668 patients) were included; 333 (49.8%) received statin therapy. Mean participant age was 39 years (range 15-51), with mean follow-up of 18.5 months. Statin therapy significantly reduced hs-CRP (MD -0.61 mg/L; 95% CI -1.12, -0.11; p = 0.017), LDL cholesterol (MD -35.49 mg/dL; 95% CI -57.14, -13.83; p < 0.01), and total cholesterol (MD -38.85 mg/dL; 95% CI -66.74, -10.95; p < 0.01) compared to placebo. No significant differences were observed in CIMT (MD -0.0047 mm; 95% CI -0.017, 0.0075; p = 0.45), CAC (SMD -0.10; 95% CI -0.34, 0.15; p = 0.45), or SLEDAI (MD -0.70; 95% CI -1.56, 0.15; p = 0.11). CONCLUSION: Statin therapy in SLE patients significantly improved inflammatory and lipid markers but showed no significant impact on structural atherosclerosis markers or disease activity. Given the low to very low certainty of the available evidence, these findings should be interpreted cautiously and confirmed in adequately powered, long-term RCTs.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.